对药品上市价值评估模糊认识的分析和探讨  

An analysis on the blurred cognition of drug market value assessment

作　　者：孙利华[1] 董旻[1] 

机构地区：[1]沈阳药科大学工商管理学院,辽宁沈阳110016

出　　处：《中国卫生政策研究》2009年第3期33-35,共3页Chinese Journal of Health Policy

摘　　要：目的:理清对我国药品上市价值评估的模糊认识,为促进药物经济学在政策层面的合理应用提供参考。方法:从药品上市价值评估的内涵出发,结合药品上市审评工作的基本目标,针对有关药品上市价值评估的一些模糊性认识进行分析和探讨。结果和结论:在药品审评环节引入药品上市价值评估是必要,但应是倡议性的要求而非强制性要求;在药品审评环节引入药品上市价值评估对企业而言增加的是机遇;而非"枷锁";药品审评环节引入药品上市价值评估不应孤立存在,药品管理各相关部门均应引入药物经济性要求。Objectives： This article aims to specify the market value of drug and eliminate the blurred cognition in order to promote pharmaceutical economic utilization for health policy reference. Methods： From the cognition of drug market value, the paper attempts to analyze the blurred cognition of drug market value and discusses the basic target of the market value evaluation of drug. Results and conclusions ： It＇s necessary to introduce drug market value evaluation in the process of drug approval. This kind of evaluation should be encouraged but not required compulsori- ly. In addition, drug market evaluation is an opportunities not a ＇lock＇ for pharmaceutical companies. And drug market evaluation in the process of approval should not be an isolated policy, in other words, pharmaceutical econom- ic analuysis should be introduced in the whole process of the drug administrations.

关 键 词：药品审评 上市价值评估 模糊认识 分析 

分 类 号：R951[医药卫生—药学]